U.S., Sept. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07831226) titled 'Safety and Immunogenicity of the Recombinant Malaria Vaccines in Healthy Adults Aged 18-59 Years' on Sept. 15.
Brief Summary: This is a clinical trial in which healthy volunteers will receive one of three investigational malaria vaccines (LYB014, LYB017, and LYB027) administered in combination with the A02B adjuvant, or the A02B adjuvant alone as the control.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Malaria Vaccine
Intervention:
BIOLOGICAL: LYB014 low dose
Dosage forms and strengths: Solution for injection. Each dose is 0.5 mL and is administered by intramuscular injection. Participants will receive...